Peer Cohort · Robust

Large-Cap Biotechnology

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · Biotechnology · 7 peers

· 7 not run

One action: refreshes every issuer report, pulls latest FMP pricing & revenue, recomputes cohort performance, then regenerates the cohort synthesis.

Peer Cohort Report

Large-Cap Biotechnology — not yet synthesized

A cohort report needs ≥2 persisted issuer reports. Run the cohort fan-out above first — currently 0 ready.

Why these companies

Profitable large-cap biotechnology companies with established franchises in oncology, virology, immunology, or rare disease. Peer set is distinct from emerging biotech given their commercialized product economics.

Cohort performance · 90 days

Large-Cap Biotechnology

…

Loading performance intelligence…

Leadership intelligence

… · last 90d

Loading leadership intelligence…

Members

7 issuers · scored first

AMGN

Covered

Amgen Inc.

NASDAQ · $37B

Amgen is a biotechnology pioneer with a strong competitive moat primarily driven…

BIIB

Covered

Biogen Inc.

NASDAQ · $10B

Biogen's moat is based on its strong position in the neuroscience market, partic…

GILD

Covered

Gilead Sciences

NASDAQ · $29B

Gilead Sciences possesses a strong competitive moat primarily through its extens…

INCY

Covered

Incyte Corporation

NASDAQ · $5B

Incyte discovers, develops, and commercializes proprietary therapeutics. Its com…

MRNA

Covered

Moderna Inc.

NASDAQ · $2B

Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics …

REGN

Covered

Regeneron Pharmaceuticals

NASDAQ · $14B

Regeneron boasts a strong competitive moat driven by its innovative drug discove…

VRTX

Covered

Vertex Pharmaceuticals

NASDAQ · $12B

Vertex Pharmaceuticals has a strong competitive moat due to its focus on develop…